| Title |
Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
|
|---|---|
| Published in |
Drugs & Aging, February 2015
|
| DOI | 10.1007/s40266-015-0248-y |
| Pubmed ID | |
| Authors |
Gillian M. Keating |
| Abstract |
Enzalutamide (Xtandi(®)) is an androgen receptor inhibitor that blocks several steps in the androgen receptor signalling pathway. This article reviews the clinical efficacy and tolerability of oral enzalutamide in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC), as well as summarizing its pharmacological properties. In the randomized, double-blind, multinational PREVAIL trial, enzalutamide significantly improved both radiographic progression-free survival and overall survival versus placebo in chemotherapy-naïve men with metastatic CRPC who were asymptomatic or mildly symptomatic. In addition, enzalutamide significantly delayed the need for chemotherapy and the decline in health-related quality of life versus placebo. Enzalutamide was generally well tolerated in chemotherapy-naïve men with metastatic CRPC. In conclusion, enzalutamide is a convenient, effective and well tolerated treatment for chemotherapy-naïve men with metastatic CRPC who are asymptomatic or mildly symptomatic. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 21% |
| Student > Bachelor | 5 | 15% |
| Researcher | 4 | 12% |
| Student > Ph. D. Student | 4 | 12% |
| Student > Postgraduate | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 10 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Computer Science | 3 | 9% |
| Nursing and Health Professions | 1 | 3% |
| Sports and Recreations | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 13 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2021.
All research outputs
#6,922,550
of 22,699,621 outputs
Outputs from Drugs & Aging
#472
of 1,192 outputs
Outputs of similar age
#78,879
of 255,346 outputs
Outputs of similar age from Drugs & Aging
#12
of 20 outputs
Altmetric has tracked 22,699,621 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,192 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 255,346 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.